Multiple Myeloma: An Old Disease with New Hope for the Future

Adnan A. Zaidi, MD; David H. Vesole, MD, PhD, FACP

ABSTRACT Multiple myeloma is a currently incurable malignancy of terminally differentiated plasma cells. It typically occurs in older patients (median age 71 years). Clinical manifestations result from monoclonal protein (immunoglobulin) production and its accumulation in the serum and/or urine, anemia, lytic bone disease, hypercalcemia, renal insufficiency, and immune deficiency. Myeloma cells have low proliferative activity—most myeloma experts opine that the initial oncogenic event occurs 10-15 years before clinical disease manifestation. In addition, myeloma cells develop multiple chromosomal abnormalities, which may explain the native resistance of myeloma patients to conventional therapy and our inability to completely eradicate the disease.

Indeed, with conventional therapy, only 5% of patients achieve complete response. Minimal improvement has been observed with conventional therapies over the past 20-30 years; the median duration of initial response remains approximately 18 months with median survival in the 36-month range. However, recent clinical trials have established high-dose therapy with autologous hematopoietic stem cell transplant as superior to conventional therapy: complete remission rates of 25-30% can be achieved with median survival exceeding 5 years.

Newer approaches to improve treatment outcomes are in active clinical trials including: more potent induction regimens utilizing thalidomide, alone or in combination with dexamethasone; tandem transplants to improve complete remission rates; newer approaches to maintenance therapy using thalidomide with corticosteroids; non-myeloablative therapy with allogeneic transplant; and post-transplant vaccinations. (CA Cancer J Clin 2001;51:273-285.)

INTRODUCTION

Multiple myeloma is a malignancy of terminally differentiated B-lymphocytes. It is characterized by the clonal proliferation of plasma cells that are innately resistant to standard doses of chemotherapy. This systemic malignancy is highly treatable but rarely curable. Although skeletal evidence for the existence of multiple myeloma has been obtained from Egyptian mummies, the major clinical features of multiple myeloma were first described around 1850 in England. Recently, tremendous advances have been made in understanding the biology and developing treatments of multiple myeloma. This article deals with etiology, diagnosis, and the current treatment options for newly diagnosed and previously treated patients with multiple myeloma. It also discusses future treatment directions.
ETIOLOGY

The etiology of multiple myeloma remains unknown. Risk factors are thought to include chronic immune stimulation, autoimmune disorders, exposure to ionizing radiation, occupational exposure to pesticides or herbicides, occupational exposure to dioxin, and perhaps, prolonged use of certain hair coloring products. Schwartz in his analysis of eight multiple myeloma “clusters,” observed an association between increased risk of multiple myeloma and proximity to dioxin-contaminated water sources and consumption of dioxin-contaminated fish. Myeloma has been associated with exposure to Agent Orange during the Vietnam War. A number of viruses have been implicated in the pathogenesis of myeloma. Patients with HIV have a 4.5-fold increased likelihood of developing myeloma, although the exact mechanisms are unclear. The recent finding of human herpesvirus 8 (HHV-8) infection in bone marrow stromal cells in multiple myeloma patients may be associated with the development and progression of the disease. HHV-8 has also been identified in stromal cells of other plasma cell dyscrasias, such as monoclonal gammopathy of undetermined significance (MGUS) and primary systemic amyloidosis, implying a potential causal association. However, this association is not universally accepted. The Myeloma Intergroup of France has identified 20 families through myeloma family studies, where the risk of developing myeloma is as high as 5%.

Hallek et al. proposed a model for the pathogenesis for multiple myeloma with an ordered progression from a normal plasma cell to MGUS to multiple myeloma. Cells are immortalized, but not transformed, when normal plasma cells progress to MGUS, and these do not progressively accumulate or cause bone destruction. Later this changes to intramedullary myeloma, where the cells are confined to the bone marrow microenvironment where they accumulate and cause bone destruction via cytokine-induced increased osteoclast activity. In some patients, the disease evolves to extramedullary myeloma, where the cells proliferate more rapidly and circulate in the peripheral blood (plasma cell leukemia) or other extramedullary sites.

Interleukin-6 (IL-6) is essential for the survival and growth of myeloma cells, which express specific receptors for this cytokine. IL-6 was initially found to be a growth factor for myeloma cells, but recently it was also shown to promote the survival of myeloma cells by preventing spontaneous or dexamethasone-induced apoptosis. There is increasing evidence that IL-6 is an autocrine and paracrine growth factor. It is produced by the myeloma cells as well as stromal cells in the bone marrow microenvironment. Myeloma cells also shed the soluble form of IL-6 receptor, which can amplify the response of myeloma cells to interleukin-6. IL-6 receptor is present in high amounts in the serum of patients with myeloma, especially those with a poor prognosis. Finally, IL-6 also has a role in the pathogenesis of bone lesions in multiple myeloma. IL-6, soluble IL-6 receptor, and interleukin-1 (beta) activate osteoclasts in the vicinity of myeloma cells and, thus, provoke bone resorption. Other growth factors that seem to be important for multiple myeloma include granulocyte-colony stimulating factor, interferon-α and interleukin-10.

EPIDEMIOLOGY

The median age at diagnosis of multiple myeloma is 71 years. Age, race and gender significantly affect the incidence. There are approximately 14,400 new cases of multiple myeloma diagnosed each year and 11,200 deaths. The overall incidence rate in the United States is 4/100,000/year. The male/female ratio is 1:4. The incidence rate in African
Americans is 9.6/100,000/year.1 With the aging of the US population, there is an increase in the cases of multiple myeloma. Myeloma accounts for 1% of all malignancies: 10% of all hematological malignancies in Caucasians and 20% in African Americans.12 The reason for the higher incidence in women and African Americans is not known. It should be emphasized that MGUS is 80-100 times more common than multiple myeloma and three-fourths of these remain without conversion to multiple myeloma over 20+ years.

Signs and Symptoms

Signs and symptoms of multiple myeloma include bone pain, which may be present in three-fourths of patients. Osteolytic lesions and compression fractures may be seen in the axial skeleton and proximal long bones—the most common being the spine. There is an increased osteoclastic activity in myeloma patients mediated by osteoclastic stimulating factors including IL-1, IL-6 and TNF. These factors are produced locally in the bone marrow microenvironment by tumor and stromal cells.13,14 These cytokines may also serve as myeloma growth factors and prevent apoptosis.

Increased bone resorption may lead to hypercalcemia, which may present as lethargy, nausea, and constipation as well as renal insufficiency in one-third of patients. Renal insufficiency is often multi-factorial but is predominantly due to the development of “myeloma kidney” in which the distal convoluted tubules and collecting tubules become obstructed with casts consisting mainly of Bence Jones (monoclonal urinary light chain) protein. There is also light chain deposition in the mesangium. Renal insufficiency occurs in one-third of all patients. Hypercalcemia exacerbates the nephrotoxicity of Bence Jones proteins.

Cytokine dysregulation leads to impaired erythropoiesis, resulting in anemia in more than 75% of patients. Many patients have low levels of endogenous erythropoietin. IL-6 and other cytokines may inhibit erythroid lineage synthesis.9 Approximately 60% of multiple myeloma patients respond to exogenous erythropoietin.

Cellular and humoral immune dysfunction are commonly observed in multiple myeloma. Susceptibility to pneumococcal pneumonia and infections with other encapsulated bacteria, is enhanced in the setting of multiple myeloma in part due to diminished production of normal immunoglobulins and subsequent opsonization. Compromised cellular immunity is manifested as an increase in the incidence of herpes zoster in multiple myeloma patients.

Neurological dysfunction is common during the course of the disease. This may be from spinal cord compression (upper motor signs) manifested as back pain, sciatica, or muscle weakness as a result of epidural encroachment by plasmacytomas; hyperviscosity (headache, blurring of vision progressive obtundation, vertigo, hemiparesis, seizure); or a demyelinating neuropathy as a paraneoplastic manifestation of the myeloma paraprotein.

Laboratory Evaluation

The standard evaluation of a patient with suspected myeloma includes:

- complete blood count with differential.
- blood chemistry profile including calcium, creatinine, LDH, albumin, and uric acid.
- bone marrow aspirate and biopsy with cytogenticics and plasma cell labeling index (this may need a reference lab).
- complete skeletal survey.
- serum and urine electrophoresis with immunofixation to identify the M protein and quantification of this protein. Urine sample should be a 24-hour urine collection. Serum protein electrophoresis (SPEP) shows a monoclonal spike in 85% of multiple myeloma patients. Urine
electrophoresis shows a globulin spike in 75% of patients. Sixty percent of the patients have a monoclonal protein that is immunoglobulin G (IgG), 20% IgA, 1% IgD or non-secretory, and 15% are light chain only.

- serum beta-2 microglobulin, C-reactive protein.

Diagnosis

Table 1 provides the diagnostic criteria for multiple myeloma, smoldering myeloma, indolent myeloma and MGUS.15

CLASSICAL STAGING SYSTEM

In 1975, the Durie-Salmon Staging System was published to distinguish patients with low (Stage I), intermediate (Stage II) and high (Stage III) volumes of tumor mass before institution of therapy (Table 2).16 Each of these three stages are divided into substages A (serum creatinine < 2 mg/dl) and B (serum creatinine ≥ 2 mg/dl). It is included for the sake of completeness and is largely of historical value.

Prognostic Factors

Although the Durie-Salmon Staging System was the classic nomenclature to stage myeloma patients, recent advances in the biology and treatment of myeloma indicate that this staging system does not accurately predict event-free and overall survival. Other parameters as shown in Table 3, seem to have more clinical significance17,18 and when available should be done as part of the initial work-up. The strongest predictors of a favorable outcome that are routinely available are low beta-2 microglobulin and C-reactive protein. Other predictors of a favorable outcome, often only available at reference laboratories, are absence of chromosome 13 abnormalities on metaphase.

---

**TABLE 1**

Diagnosis of Multiple Myeloma, Indolent Myeloma, Smoldering Myeloma, and Monoclonal Gammopathy of Undetermined Significance (MGUS)

### Multiple Myeloma

**Major Criteria**

I. Plasmacytoma on tissue biopsy
II. Bone marrow plasmacytosis with > 30% plasma cells
III. Monoclonal globulin spike on serum electrophoresis
   - > 3.5 g/dl for IgG
   - > 2 g/dl for IgA
   - ≥ 1 g/24 hr for κ or λ Bence Jones proteinuria

**Minor Criteria**

a. Bone marrow plasmacytosis 10-30%
b. Monoclonal globulin spike
   - < 3.5 g/dl for IgG
   - < 2 g/dl for IgA
   - ≤ 1 g/24 hr for κ or λ Bence Jones proteinuria
c. Lytic bone lesions
d. Uninvolved immunoglobulin levels IgM < 50 mg/dl, IgA < 100 mg/dl, or IgG < 600 mg/dl

**Diagnosis of Multiple Myeloma**

In a symptomatic patient requires a minimum of one major + one minor criterion

- I + b, I + c, I + d (not I + a)
- II + b, II + c, II + d
- III + a, III + c, III + d

or three minor criteria that must include a + b

- a + b + c or a + b + d

### Indolent Myeloma

No bone lesions or limited bone lesions (≤ 3 lytic lesions) no compression fractures

M protein levels IgG ≤ 7 g/dl, IgA ≤ 5 g/dl

No symptoms or associated disease features

- Performance status > 70%
- Hemoglobin > 10 g/dl
- Serum calcium normal
- Serum creatinine < 2 mg/dl
- No infections

### Smoldering Myeloma

Same as indolent myeloma except:

- No bone lesions
- Bone marrow plasma cells ≤ 30%

### Monoclonal Gammopathy of Undetermined Significance (MGUS)

Monoclonal gammopathy

M protein level: IgG ≤ 3.5 g/dl, IgA ≤ 2 g/dl, BJ protein ≤ 1 g/24 hr

Bone marrow plasma cells < 10%

No bone lesions, no symptoms
cytogenetic karyotyping (or more recently by fluorescent in situ hybridization; FISH) and low plasma cell labeling index.

## TREATMENT

### Supportive Care

Skeletal involvement often leads to pain, pathological fractures, hypercalcemia, or cord compression. These complications result from increased osteoclastic bone resorption. Bisphosphonates are inhibitors of osteoclastic activity. Bisphosphonates may reduce tumor burden by changes in bone microenvironment, as well as promoting apoptosis of tumor cells and, thus, may have a direct effect on multiple myeloma. Therefore, patients with multiple myeloma who have lytic bone lesions or osteopenia should be given bisphosphonates. Pamidronate should also be used in cases of persistent hypercalcemia. The currently available bisphosphonate, pamidronate, has been shown to reduce skeletal complications and skeletal morbidity and to improve quality of life. Pamidronate is administered over 1-2 hours intravenously (90 mg) every four weeks. In addition to the reduction in skeletal events and bone pain, one randomized study suggests that some subgroups of patients treated with pamidronate have improved disease-free and overall survival compared with placebo. A newer bisphosphonate, zoledronic acid, will soon be available. This is a more potent bisphosphonate (100 to 1000-fold in vitro) that can be infused over a shorter period (15 minutes).

Anemia occurs in almost all multiple myeloma patients during their disease course. Up to 60% of patients respond to erythropoietin injections even in the absence of renal insufficiency. There is a significant improvement in the patients’ quality of life and sense of well being.

### Infections

Infections are common in myeloma patients in part due to decreased production of normal immunoglobulins. Patients who present with fever should be evaluated with appropriate cultures and radiographic studies and started on antibiotics. Streptococcal infections are a particular concern. Fever is rarely due to myeloma itself and an infectious etiology should be sought. The use of daily oral trimethoprim-sulfamethoxazole (TMP-SMX) or some other broad-spectrum antibiotic such as a fluoroquinolone may be helpful when administered prophylactically during initial therapy. To further investigate the importance of prophylactic antibiotics, there is an international randomized trial comparing fluoroquinolones versus TMP-SMX versus observation in newly diagnosed patients during the first two months of therapy (U1099).

### Assessment of Tumor Mass

#### TABLE 2

| Assessment of Tumor Mass |
|--------------------------|
| **High Tumor Mass (Stage III) (> 1.2 x 10¹² tumor cells/m²)** |
| One of the following abnormalities must be present: |
| Hemoglobin < 8.5 g/dl |
| Serum calcium > 12 mg/dl |
| Very high myeloma protein production |
| IgG peak > 7 g/dl |
| IgA peak > 5 g/dl |
| Bence Jones protein > 12 g/24 hour |
| > 3 lytic lesions on bone survey (bone scan not acceptable) |
| **Low Tumor Mass (Stage I) (< 0.6 x 10¹² malignant cells/m²)** |
| All of the following must be present: |
| Hemoglobin > 10.5 g/dl or hematocrit > 32 volume % |
| Serum calcium normal |
| Low myeloma protein production |
| IgG peak < 5 g/dl |
| IgA peak < 3 g/dl |
| Bence Jones protein < 4 g/24 hour |
| No bone lesions |
| **Intermediate Tumor Mass (Stage II) (0.6-1.2 x 10¹² malignant cells/m²)** |
| All patients who do not qualify for high or low tumor mass are considered to have intermediate tumor mass. |

---

*CA Cancer J Clin 2001;51:273-285*
Patients who have IgA multiple myeloma have an increased risk for hyperviscosity due to the dimeric and polymeric forms of the IgA molecule. Hyperviscosity is characterized by oral bleeding, epistaxis, blurred vision, headache, sausaging of retinal veins, paresthesias, or congestive heart failure. Plasmapheresis should be promptly initiated if the patient has signs and symptoms of hyperviscosity. Serum viscosity is measured by a blood test available in most hospital laboratories.

### TABLE 3
Favorable Prognostic Factors in Multiple Myeloma

| Factor                                                                 | Value                  |
|------------------------------------------------------------------------|------------------------|
| Beta-2 microglobulin                                                   | ≤ 2.5 mg/l*            |
| C-reactive protein                                                    | ≤ 4.0 mg/dl*           |
| No -13/13q- chromosome abnormalities                                  |                        |
| Plasma cell labeling index less than 1%                               |                        |
| Absence of plasmablastic morphology                                   |                        |
| ≤ 12 months prior treatment                                           |                        |
| Chemotherapy sensitive disease                                        |                        |
| Any complete remission                                                |                        |
| Non IgA isotype (controversial)                                       |                        |
| Low Interleukin-6 receptor                                            |                        |
| * Routinely available to all physicians and should be done as part of initial work-up. |

*Improvement in treatment outcomes. A meta-analysis of 27 trials and 6,633 myeloma patients, comparing treatment with melphalan and prednisone to combination chemotherapy, revealed no significant difference in the survival of patients receiving either of these two forms of therapy. Cumulative exposure to melphalan, however, is associated with an increasing risk of marrow toxicity, including myelodysplasia, acute leukemia and impaired stem cell production. This is an important consideration in patients who are candidates for high dose therapy with stem cell rescue (autologous transplants).

With conventional therapy, only 5% of patients achieve complete remission. Molecular analysis shows rapid development of MDR1 (multidrug resistance 1) gene expression in multiple myeloma patients. Attempts at overcoming drug resistance due to MDR1 activity (e.g., PSC 833, cyclosporine, quinine, verapamil) have met with limited success and are associated with increased toxicity.

Salvage therapy is needed for patients who have either relapsed or have primary refractory disease. VAD (vincristine + Adriamycin + dexamethasone) benefits 40-50% of relapsing patients and about 30% of those with primary unresponsive disease. The most active agent in the combination is dexamethasone. High dose dexamethasone pulsing alone induces responses in about 30-40% of patients regardless of prior response. Thalidomide was recently reported as effective salvage therapy in patients with refractory multiple myeloma. Singhal et al. reported a response rate of 32% in heavily pretreated patients with oral thalidomide as a single agent. Reduction in paraprotein was evident within 2 months in most responders. Thalidomide is reasonably well tolerated; the toxicities include somnolence, constipation, and occasionally peripheral neuropathy. The mode of action of thalidomide is unknown: Angiogenesis inhibition, possibly by down-regulation of VEGF (vascular endothelial...
growth factor), immune modulation, by increasing NK cell activity, interleukin-2 and gamma interferon, and increasing apoptosis have been proposed. Thalidomide combined with dexamethasone pulsing has shown promising results in previously treated and in newly diagnosed patients. Thalidomide combined with conventional chemotherapy agents as salvage therapy and induction therapy is under investigation. Thalidomide as maintenance therapy is also actively being studied.

AUTOLOGOUS TRANSPLANTS

With conventional therapy, there has been minimal improvement in treatment outcomes for multiple myeloma in the past 15-20 years. To overcome the native (at the time of diagnosis) resistance of myeloma cells to conventional chemotherapy, high-dose therapy requiring autologous hematopoietic stem cell support was first evaluated in patients with refractory disease. This resulted in improved response rates and survival. This approach was then extended to newly diagnosed patients. In 1996, the seminal randomized study on symptomatic stage II and III patients by the French Myeloma Intergroup showed conclusively that high-dose therapy yielded a superior disease-free and overall survival outcome compared with conventional therapy. The 5-year projected survival for the transplant group was 52% versus 12% for the conventional therapy group. Whereas complete responses were observed in only 5% of the conventional therapy group, 22% of the high-dose therapy group achieved complete remissions. The transplant-related mortality was only 2.7%. In a non-randomized trial, the University of Arkansas group has used tandem transplants as consolidation therapy for newly diagnosed multiple myeloma patients. The researchers observed overall response rates exceeding 75% and complete response rates (intent-to-treat) of 38% following tandem transplants. Transplant-related mortality was less than 8% at one year for all patients and for patients less than 65 it was closer to 1%. Patients achieving complete response had a median disease-free survival of 50 months and median overall survival more than 7 years.

In general, high-dose therapy with autologous transplant nearly doubles median survival for newly diagnosed patients. High-dose therapy with autologous stem cell transplantation is now considered appropriate care for front-line therapy in many newly diagnosed multiple myeloma patients, particularly those younger than 70 years of age. High-dose therapy with autologous transplant for patients with disease relapse has not been evaluated in randomized or pair-matched case controls. In previously treated patients with chemotherapy sensitive relapse, 75% of transplanted patients achieved 75% tumor reduction, including true complete responses of 10-15%. The median relapse-free survival and overall survival is on the order of 2 and 3 years, respectively. In patients with refractory relapse, high-dose therapy with autologous stem cell transplant resulted in a median event-free survival and overall survival of 11 and 19 months, respectively.

Although high-dose therapy with autologous transplantation is now considered appropriate care for many newly diagnosed patients, there are still clinical investigations into the timing of transplant—either upfront as consolidation therapy or as salvage therapy at the time of relapse. A French Myeloma Intergroup study did not show a significant difference in overall survival when they randomized 184 patients to early versus late transplant (median survival approximately 5 years). They did observe a superior quality of life in the early transplant group since the disease-free survival was 39 months versus 13 months. The North American Intergroup
study (S9321) comparing early to late transplant met its accrual goal in October 2000. Results of this trial are not expected for 2–3 years.

Another area of clinical research is whether tandem transplant is superior to single transplant. The Arkansas group has reported improved complete remissions with tandem transplant with the best results observed in patients with less than 12 months of prior therapy who received tandem transplants within 6 months.13,17,45 The French Myeloma Intergroup has completed a randomized trial comparing single with tandem transplant. The final analysis of this trial is not yet completed. The preliminary results show no difference in overall survival between groups at a median follow-up of 4 years.49 However, in the most recent subgroup analysis, patients receiving tandem transplants with peripheral blood stem cell support had a superior outcome to patients receiving tandem bone marrow transplants or single stem cell or bone marrow transplants. In addition there are two other randomized trials comparing single to tandem transplant, which have not been completed. Until the final analysis of these trials is available, tandem transplants cannot be considered standard of care.

Transplant-related mortality is low, less than 3% in patients younger than 65 years and 5–8% in patients older than 65 years.50 Unfortunately, even with tandem transplants, there does not appear to be a plateau in post-transplant survival curves indicating that cures are unlikely with this approach.17,43-48 Novel new approaches are imperative to improve outcomes.

ALLOGENEIC BONE MARROW TRANSPLANT

As indicated above, the use of high-dose therapy with autologous hematopoietic stem cell transplant has been shown to be superior to conventional therapy. However, there does not appear to be a plateau in the disease-free survival indicating that cures with autologous transplantation are unlikely. This may be due to either infusion of stem cell grafts contaminated with myeloma cells and/or the inability to eradicate minimal residual disease even with tandem transplants.

Allogeneic transplantation offers two advantages: The absence of tumor-contaminated grafts and the benefit of a graft-versus-myeloma effect.51,52 Compared with autologous transplantation, fewer allogeneic transplants have been performed. This is due to the advanced age (median 71 years) at diagnosis and limited availability of histocompatible donors; less than 10% of patients are candidates for allotransplantation. Although long-term, disease-free survival has been observed following allotransplantation, the treatment-related mortality for multiple myeloma is excessively high, ranging from 20% to 50% in the first 100 days post-transplant.53,54 The North American Intergroup trial (S9321) allowed allogeneic transplantation in patients younger than 55 who had HLA identical sibling donors. Patients underwent allogeneic transplantation following four cycles of VAD and high-dose cyclophosphamide (4.5 g/m²). This arm of the study was prematurely closed when the transplant-related mortality was 41% in the first 36 patients (R. Kyle, personal communication).

Patients who survive the initial transplant-related toxicities have prolonged disease-free outcomes and may be cured. The European Blood and Marrow Transplant Registry (EBMT) have reported the largest database. Gharton et al.55 reported an improvement in treatment outcomes with allogeneic bone marrow transplantation over the preceding 5 years due to a significant improvement in survival, which was the result of a reduction in transplant-related mortality. The median survival with allogeneic transplantation from 1984–1993 was 12 months and from 1994–1999, the median survival had improved to 43 months. Before 1994, transplant-related mortality at 12 months was 40% compared with 20% after 1994 due to de-
increased incidence in infectious pulmonary complications. An additional evaluation of the EBMT database compared the outcomes of syngeneic, allogeneic and autologous transplantation. The overall 4-year survival rate with syngeneic transplantation was 77%, with autotransplantation 46%, and with allotransplantation 31%.56

There is evidence that immune regulation may be a vital component of the high response rates and low relapse rates following allogeneic transplantation for multiple myeloma. A number of small studies have observed a graft-versus-myeloma effect using donor leukocyte infusions or immunosuppression withdrawal for patients who have relapsed following allogeneic transplant.51,52 Approximately 50% of patients respond with a graft-versus-myeloma effect to donor leukocyte infusions. This was most frequently observed in patients with a concomitant graft-versus-host disease. Unfortunately, many of these responses were not durable.

As indicated above, the transplant-related mortality with allogeneic transplant is exceedingly high. No specific prognostic factor has been determined to explain the higher transplant-related mortality. Most clinicians are hesitant to subject a patient to this risk knowing that autologous transplants result in median overall survival of 5+ years. However, recently, a number of transplant centers have been using non-myeloablative transplants (“mini-transplants”) for a number of hematologic malignancies including multiple myeloma.57,58 The basis of the ‘mini-transplant’ is to provide sufficient immune suppression to allow donor engraftment and subsequent graft-versus-tumor effect. Preliminary data showed a high rate of complete remission, even in heavily treated patients with resistant disease.57 At the American Society of Hematology meeting in December 2000, there were 120 abstracts describing non-myeloablative therapy. A number of these included patients with multiple myeloma, including one by Lalancette et al. that presented the European Bone Marrow Transplant Registry results from 50 patients.59 All patients engrafted, 20 of 27 evaluable patients achieved 95% donor engraftment: New complete remission (CR) was observed in 16, continuous CR (CCR) 1, new partial remission (PR) 7, continuous PR 12. Transplant-related mortality at one year was 32%, relapse incidence 13%. The actuarial survival at one and two years was 54% and 40%, respectively. Unfortunately, most responses were not durable. To improve outcomes with this approach, the Eastern Cooperative Oncology Group will soon initiate a protocol using an autologous transplant for maximal tumor cytoreduction to be followed by a “mini-transplant” intended to eradicate minimal residual disease (E4A98). A pilot trial using this approach has shown high response rates (53% CR).59

**MAINTENANCE THERAPY**

**Interferon**

The use of interferon for maintenance therapy following conventional chemotherapy is controversial. Although there are data that indicate interferon slightly improves relapse-free survival following conventional therapy, there is only a single study suggesting that interferon improves overall survival.60 Although an initial study from the Italian Myeloma study group in 1990 reported improvement in relapse-free and overall survival with interferon maintenance therapy,61 a 10-year follow-up report by this group did not show any survival advantage.62 A meta-analysis of 24 randomized trials consisting of more than 4000 patients treated with interferon showed a minimal benefit in relapse-free and overall survival to the interferon-treated patients.63 In autologous transplants, a single randomized trial of maintenance interferon following high-dose
melphalan initially suggested a survival benefit, but longer follow-up revealed no survival benefit. Consequently, outside of a clinical trial, IFN therapy cannot be strongly recommended for maintenance therapy.

Steroids

The Southwest Oncology Group reported improved relapse-free and overall survival using prednisone maintenance therapy. Patients responding to VAD were randomized to either 10 mg or 50 mg of prednisone every other day until relapse. Patients receiving the higher prednisone dose (50 mg) had improved outcomes without any significant differences in toxicities.

FUTURE DIRECTIONS

Current clinical investigations are aimed at improving disease outcomes in each of the principle treatment phases: Induction therapy, high-dose therapy, maintenance and salvage therapy.

Induction Therapy

Since the Centers for Medicare and Medicaid Services (formerly the Health Care Financing Administration) now approves reimbursement of high-dose therapy with autologous transplant for newly diagnosed patients (and select previously treated patients) up to age 78, patients being considered for transplantation should not receive alkylating agent-based induction therapy, which may compromise future transplant options. Recent data indicate that thalidomide combined with high-dose dexamethasone pulsing results in response rates of more than 75%. This combination alleviates the need of 96-hour chemotherapy infusions, insertion of indwelling catheters and the subsequent risk of catheter-associated thrombosis in patients receiving VAD chemotherapy. The Eastern Cooperative Oncology Group is planning a Phase II clinical trial comparing induction therapy with dexamethasone alone versus dexamethasone/thalidomide. The Arkansas group is currently completing “Total Therapy II” which uses thalidomide for induction pre-transplant and as maintenance therapy post-transplant.

Holmium–DOTMP is referred to as a skeletal targeted radiotherapy (STR) product. The β radiation is provided by the 166Holmium and is attached to DOTMP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonic acid), which is a drug that is bone seeking. This selective radiation minimizes toxicity. Holmium–DOTMP has been used with high-dose chemotherapy as preparation for auto-logous stem cell transplantation in patients with multiple myeloma; the therapy was well tolerated with a complete response rate of 53%. Another skeletal targeted radiotherapeutic compound, 153Samarium is also being combined with high-dose chemotherapy with autologous stem cell transplant. Phase III studies will be needed to further assess the overall impact on remission rates and survival.

The regimen-related toxicities of most high-dose therapy regimens are oral mucositis and gastrointestinal toxicity. These prevent the full exploitation of the log-linear dose-response effect of certain antineoplastic agents. To increase the maximum tolerated dose of high-dose therapy, trials using cytoprotective agents, such as amifostine or keratinocyte growth factor, are actively being pursued with promising preliminary results. It is hoped that increased dose intensity will result in higher response rates and improved survival.

Maintenance Therapy

Following the success of thalidomide in the salvage setting, thalidomide is now being
evaluated as maintenance therapy either alone or with corticosteroids.

Another new area is the development of vaccines. Several studies have demonstrated that myeloma protein, also called idiotype (Id), is sufficiently immunogenic and can be used to generate in vivo T-cell and B-cell responses in myeloma patients. Clinical trials using Id-pulsed dendritic cells (DC) as a vaccine to treat minimal residual disease or relapsed myeloma are currently underway. Feasibility studies indicate that antigen-pulsed autologous DCs can be used to elicit in vivo Id-specific T-cell and B-cell responses. Additional studies are needed to optimize current DC vaccination protocols and determine clinical benefits associated with this approach. Interleukin-2 (IL-2) alone or with GM-CSF is also being used with or without vaccines to effect immunomodulation. Data suggest that high serum levels of IL-2 correlate with longer survival in patients with multiple myeloma. Animal and laboratory studies indicate that IL-2 has anti-tumor activity. Non-myeloablative “mini transplants” are being refined and these may offer the potential for cure with reduced toxicity. Again, longer follow-ups are needed.

### Rescue Therapy

As discussed above, thalidomide has been shown to be an effective therapeutic modality in the setting of disease relapse. Thalidomide is now being used with other chemotherapeutic agents. The University of Arkansas group study of two combination chemotherapy regimens: DT-PACE (combining dexamethasone, thalidomide-cisplatin, adriamycin, cyclophosphamide, and etoposide) and DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) indicated remarkable activity in far advanced and high-grade multiple myeloma. Arsenic trioxide has also been shown to be active against high-risk refractory multiple myeloma with 23% response rates when used alone or with butathione sulfoximine (BSO). Pilot trials are in development including farnesyl transferase inhibitors (FTI), angiogenesis inhibitors, such as immunomodulatory thalidomide derivatives (IMiDs), 2-methoxy estradiol (2-ME2), the proteasome inhibitor LDP-341, shark cartilage derivatives (Neovastat; AE941), and agents to increase apoptosis such as bcl-2 oligo-nucleotide antisense proteins (Genasense).

### CONCLUSION

Newly diagnosed patients up to the age of 78 (HCFA guidelines) should be considered for autologous stem cell transplantation. Patients under the age of 70 with an HLA compatible donor should be considered for a non-myeloablative “mini-transplant” in clinical trials. With relapsed patients, steroids with thalidomide appear to be the most promising intervention. Patients with chemosensitive disease should be considered for salvage high-dose therapy followed by autologous transplants or non-myeloablative allogeneic transplant. Patients should be sent to centers of excellence with a focus in multiple myeloma for clinical trials whenever possible. This will help advance our understanding of disease biology and refine treatment options. With an improved understanding of the myeloma biology, and with target therapy tailored to each patient, the goal of a cure in this disease has never been more promising.
Multiple Myeloma: An Old Disease with New Hope for the Future

REFERENCES

1. Schwartz GG. Multiple myeloma: clusters, clues and dioxins. Cancer Epidemiol Biomarkers Prev 1997;6:49-56.
2. Bertazzi P, Pesatori A, Bernucci I, et al. Dioxin exposure and human leukemias and lymphomas. Lessons from the Seveso accident and studies on industrial workers. Leukemia 1999;13 Suppl 1:S72-S74.
3. Committee to Review Health Effects in Vietnam Veterans of Exposure to Herbicides. Division of Health Promotion and Disease Prevention. Institute of Medicine. Cancer in: Veterans and Agent Orange: Health Effects of Herbicides Used in Vietnam. Washington, D.C.: National Academy Press, 1994, pp 433-500.
4. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998;351:1833-1839.
5. Rettig MB, Ma HJ, Vesio RA, et al. Kaposis sarcoma–associated herpes virus infection of bone marrow dendritic cells from multiple myeloma patients (see comments). Science 1997;276:1851-1854.
6. Schonrich G, Rafferty M, Schnitzler P, et al. Absence of a correlation between Kaposis sarcoma–associated herpesvirus (KSHV/HHV-8) and multiple myeloma (letter). Blood 1998;92:3474-3475.
7. Grosbois B, Jego P, Attal M, et al. Familial multiple myeloma: report of fifteen families. Br J Haematol 1999;105:768-770.
8. Hallek M, Berg REPL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3-21.
9. Baralle R, Harousseau JL. Multiple myeloma. N Engl J Med 1997;336:1657-1664. Review.
10. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer Statistics 2001. CA Cancer J Clin 2001;51:15-36.
11. Kies LA, Eisner MP, Kosary CL, et al (eds). SEER Cancer Statistics Review 1973-1996. Bethesda, MD, National Cancer Institute, 2001.
12. Young JL, Percy CL, Asire AJ, et al. (eds.). Surveillance, Epidemiology, and End Results: Incidence and Mortality Data 1973-1977. NCI Monograph 57. Bethesda MD, Department of Health and Human Services, NIH, 1981.
13. Stachenko P, Dewhirst FE, Peros WJ, et al. Synergistic interactions between interleukin 1, tumor necrosis factor and lymphotixin in bone resorption. J Immunol 1987;138:1464-1468.
14. Mundy GR. Mechanism of osteobone destruction. Bone 1991;12 Suppl 1:S1-56. Review.
15. Salmon SE, Cassady JR. Plasma Cell Neoplasms, in: Devita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, ed 5. Philadelphia, Lippincott-Raven Publishers, 1997, pp 2534.
16. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. 1975;Cancer 36:842-854.
17. Desikan R, Barlogie B, Sawyer J, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome abnormalities. Blood 2000;95:4008-4010.
18. Rajkumar SV, Greipp PR. Prognostic factors in multiple myeloma. Hematol Oncol Clin North Am 1999;13:1295-1314, xi. Review.
19. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent human erythropoietin receptor agonist. Br J Pharmacol 1996;98:745-751.
20. Shipman CM, Rogers MJ, Apperly JF, et al. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumor activity. Br J Haematol 1997;98:665-672.
21. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Ardia Study Group. N Engl J Med 1996;334:488-493.
22. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced MM patients reduces skeletal events. Myeloma Ardia Study Group. J Clin Oncol 1998;16:593-602.
23. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:1191-1200.
24. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of parameters of response. Blood 1995;86:4446-4453.
25. Ludwig H. Epoetin in cancer-related anaemia. Nephrol Dial Transplant 1999;14 Suppl 2:85-92.
26. Oken MM, Pomeroy C, Weisdorf D, et al. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 1996;100:624-628.
27. Gertz MA, Kyle RA. Hyperviscosity syndrome. J Intensive Care Med 1995;10:128-141.
28. Kyle RA. Newer approaches to the management of multiple myeloma. Cancer 1993;72:11 Suppl:3489-3494.
29. Bergdahl DE, Sprague CC, Austin C, et al. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV-L-phenylalanine mustard (NSC-3806). Cancer Chemother Rep. 1962:21:87-99.
30. [No authors listed] Combination chemotherapy vs melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol 1998;16:3832-3842.
31. Govindarajan R, Jagannath S, Flick JT, et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996;95:349-353.
32. Dalton WS, Crowley J, Salmon SS, et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 1995;75:815-20.
33. Barlogie B, Smith L, Alexanian R, et al. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;310:1353-1356.
34. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986;105:8-11.
35. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571.
36. Dimopoulos MA, Zervas K, Galani E, et al. Thalidomide and dexamethasone combination for multiple myeloma refractory to dexamethasone-based regimens in Blood: The Proceedings of the 42 Annual Meeting and Exposition of the American Society of Hematology, San Francisco, CA, December 1-5, 2000. Philadelphia, W.B. Sanders Co., 96:296b, 2000, Abstract 4978.
37. Pulumbo A, Giacalone L, Bertola A, et al. Thalidomide and dexamethasone as salvage therapy for refractory and relapsed myeloma in Blood: The Proceedings of the 42 Annual Meeting and Exposition of the American Society of Hematology, San Francisco, CA, December 1-5, 2000. Philadelphia, W.B. Sanders Co., 96:296b, 2000, Abstract 5004.
38. Rajkumar SV, Hayman S, Fosca R, et al. Thalidomide plus dexamethasone (Thal/Dex) and thalidomide alone (Thal) as first line therapy for newly diagnosed myeloma (MM) in Blood: The Proceedings of the 42 Annual Meeting and Exposition of the American Society of Hematology, San Francisco, CA, December 1-5, 2000. Philadelphia, W.B. Sanders Co., 96:168a, 2000, Abstract 722.
39. Moehler TM, Neben K, Hawighorst H, et al. Thalidomide plus CED chemotherapy as salvage therapy in poor prognosis multiple myeloma in Blood: The Proceedings of the 42 Annual Meeting and Exposition of the American Society of Hematology, San Francisco, CA, December 1-5, 2000. Philadelphia, W.B. Sanders Co., 96:290b, 2000, Abstract 4996.
40. Munshi N, Desikan R, Zangari M, et al. Chemotherapy with DT-PACE for previously treated multiple myeloma (MM). in Blood: The Proceedings of the 41 Annual Meeting and Exposition of the American Society of Hematology, New Orleans, LA, December 3-7, 1999. Philadelphia, W.B. Sanders Co., 1999: 94: 123a, Abstract 541.
41. Castro J, Talavera A, Tejeda C, et al. Preliminary experience of the use of thalidomide maintenance therapy after autologous transplant in patients with multiple myeloma (MM) in Blood: The Proceedings of the 42 Annual Meeting and Exposition of the American Society of Hematology, San Francisco, CA, December 1-5, 2000. Philadelphia, W.B. Sanders Co., 96:367b, 2000, Abstract 5342.
42. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma–cell leukaemia and myeloma. Lancet. 1983;2:822-824.
43. Vesole DH, Barlogie B, Jagannath S, et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood 1994;94:950-956.
44. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in
multiple myeloma. N Engl J Med 1996;335:91-97.
45. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55-65.
46. Vesole DH, Tricot G, Jagannath S, et al. Autotransplants in multiple myeloma: What have we learned? Blood 1996;88:838-847.
47. Vesole DH, Crowley JJ, Cachtourian R, et al. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. J Clin Oncol 1999;17:2173-2179.
48. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92:3131-3136.
49. Attal MM, Harousseau JJ, Facon TT, et al. Single versus double transplantation in myeloma: A prospective randomized trial of the Inter Groupe Francophone du Myelome (IFM) in Blood: The Proceedings of the 42 Annual Meeting and Exposition of the American Society of Hematology, San Francisco, CA, December 1-5, 2000. Philadelphia, W.B. Sanders Co., 96: 557a, 2000, Abstract 2393.
50. Siegel DS, Desikan KR, Metha J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999;93:51-54.
51. Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma effect: proof of principle. Blood 1996;87:1196-1198.
52. Lokhorst HM, Schultenborg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000;18:3031-3037.
53. Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996;88:2787-2793.
54. Gahorton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplant for multiple myeloma. J Clin Oncol 1995;13:1312-1322.
55. Gahorton G, Svensson H, Cavo M, et al. Allogeneic and syngeneic transplantation in multiple myeloma. Presented at the VIIth International Multiple Myeloma Workshop in Stockholm, Sweden, September 1-5, 1999. Abstract 134.
56. Gahorton G, Svensson H, Bjorkstrand B, et al. Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1999;24:741-745.
57. Giral S, Weber D, Alemán A, et al. Non myeloma-like conditioning with fludarabine/melphalan for patients with multiple myeloma. In Blood: The Proceedings of the 41 Annual Meeting and Exposition of the American Society of Hematology, New Orleans, LA, December 3-7, 1999. Philadelphia, W.B. Sanders Co., 1999: 347a, Abstract 1549.
58. Lalancette M, Rezvani D, Szyllo R, et al. Excellent outcome of non-myeloablative stem cell transplant (NMSTCT) for good risk myeloma: the EBMT experience. Blood: The Proceedings of the 42 Annual Meeting and Exposition of the American Society of Hematology, San Francisco, CA, December 1-5, 2000. Philadelphia, W.B. Sanders Co., 96: 204a, 2000, Abstract 872.
59. Molina A, Sahebi F, Maloney DG, et al. Non-myeloblast peripheral blood stem cell (PBSC) allografts following cytotoxic autotransplants for treatment of multiple myeloma (MM) in Blood: The Proceedings of the 42 Annual Meeting and Exposition of the American Society of Hematology, San Francisco, CA, December 1-5, 2000. Philadelphia, W.B. Sanders Co., 96: 480a, 2000, Abstract 2063.
60. Brownson GP, Bergsagel D, Sicheri D, et al. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1995;13:2584-2586.
61. Mandelli F, Aveniti G, Amadori S, et al. Maintenance treatment with recombinant interferon-alpha-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990;322:1430-1434.
62. Pulsoni A, Avisiati G, Petrucci MT, et al. The Italian experience on interferon as maintenance treatment in multiple myeloma: ten years after (letter). Blood 1998;92:2184-2186.
63. Myeloma Trialists’ Collaborative Group. The role of interferon (IFN) as therapy for multiple myeloma: an overview of 24 randomised trials with over 4000 patients. Proceedings of the American Society of Clinical Oncology, Los Angeles, CA, May 16-18, Baltimore, MD. Lippincott Williams & Wilkins, 1998. 17: 8a, Abstract 28.
64. Cunningham D, Powles R, Malpas J, et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long term follow-up results. Br J Haematol 1998;102:495-502.
65. Berenson J, Crowley J, Barlogie B, et al. Alternate day oral prednisone maintenance therapy improves progression-free and overall survival in multiple myeloma patients. In Blood: The Proceedings of the 41 Annual Meeting and Exposition of the American Society of Hematology, Miami Beach, FL, December 4-8, 1999, Philadelphia, W.B. Sanders Co., 1998: 318a, Abstract 1305.
66. Giralt S, Champlin R, Goodman M, et al. Preliminary results of a phase I/II study of multiple myeloma (MM) patients treated with 166Holmium-DOTMP in combination with high dose melphalan +/- total body irradiation (TBI) with autologous stem cell transplant (ASCT) in Blood: The Proceedings of the 42 Annual Meeting and Exposition of the American Society of Hematology, San Francisco, CA, December 1-5, 2000. Philadelphia, W.B. Sanders Co., 96: 758a, 2000, Abstract 3281.
67. Hill BT, Perrin D, Kruczyński A. Inhibition of RAS-targeted protein: protein farnesyl transferase inhibitors revisited. Crit Rev Oncol Hematol 2000: 33:7-23. Review.
68. Phillips GL, Hale GA, Howard DS, et al. Amifostine (AMI) cytoprotection (CP) of escalating doses of melphalan and autologous hematopoietic stem cell transplantation (AHSCST): a phase II-III study. Proceedings of the American Society of Clinical Oncology, New Orleans, LA, May 21-23, Baltimore, MD. Lippincott Williams & Wilkins, 2000, 20: 49a, Abstract 189.
69. Kwak LW, Taub DD, Duffey PL, et al. Transfer of myeloma idotype-specific immunity from an actively immunized marrow donor. Lancet 1995;345:1016-1020.
70. Reiterich VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma—a feasibility study. Blood 1999;93:2411-2419.
71. Stevenson FK, Link CJ Jr, Traynor A, et al. DNA vaccination against multiple myeloma. Semin Hematol 1999;361 Suppl 3:38-42.
72. Miller JS, Wendorf D, Vesole DH, et al. Post-transplant immunotherapy in patients with multiple myeloma using concurrent lymphoid (IL-2) and antigen-presenting (GM-CSF) stimulation. In Blood: The Proceedings of the 41 Annual Meeting and Exposition of the American Society of Hematology, New Orleans, LA, December 3-7, 1999. Philadelphia, W.B. Sanders Co., 1999: 94: 312b, abstract 4623.
73. Desikan R, Fassa A, Munsch N, et al. Intensive consolidation therapy after tandem transplants further improves the outcome of multiple myeloma (MM) patients: Blood: The Proceedings of the 42 Annual Meeting and Exposition of the American Society of Hematology, San Francisco, CA, December 1-5, 2000. Philadelphia, W.B. Sanders Co., 96: 169a, 2000, Abstract 730.
74. Munsch N, Desikan, R, Zangari M, et al. Marked antitumor effect of arsenic trioxide in high risk refractory MM. in Blood: The Proceedings of the 41 Annual Meeting and Exposition of the American Society of Hematology, New Orleans, LA, December 3-7, 1999. Philadelphia, W.B. Sanders Co., 1999: 94: 123a, abstract 541.
75. Garenhaus RB, Prachand S, Fordon LI. Enhanced cytotoxicity to arsenic trioxide in resistant multiple myeloma by butyrate sulfone. (BSO): Blood: The Proceedings of the 42 Annual Meeting and Exposition of the American Society of Hematology, New Orleans, LA, December 3-7, 1999. Philadelphia, W.B. Sanders Co., 1999: 94: 123a, Abstract 541.